<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities and Exchange Act of 1934
Date of report (Date of earliest event reported): December 21, 2000
VERTEX PHARMACEUTICALS INCORPORATED
(Exact name of registrant as specified in its charter)
Massachusetts
(State of incorporation)
000-19319 04-3039129
(Commission File No.) (IRS Employer Identification No.)
130 Waverly Street
Cambridge, MA 02139
(Address of principal executive offices and zip code)
Registrant's telephone number, including area code: (617) 577-6000
<PAGE>
Item 5. OTHER EVENTS
Richard H. Aldrich has resigned his position as Senior Vice President and
Chief Business Officer of Vertex Pharmaceuticals Incorporated. Mr. Aldrich will
continue to have a role at Vertex, reporting to Joshua Boger, Ph.D., Chairman
and CEO, on issues of strategy, business development and collaborations.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
VERTEX PHARMACEUTICALS INCORPORATED
Dated: December 21, 2000 By: /s/ Joshua S. Boger
-----------------------------
Joshua S. Boger
CEO
